

ABSTRACT

The present invention relates to the use of type I polymerized collagen in Covid-19 positive patients and to an intramuscular dosing regimen every 12 h for 3 days and
5 then every 24 h for 4 days in patients with mild to moderate Covid-19 disease, or an intramuscular dosing regimen every 12 h for 7 days in patients with severe to semi-critical illness due to Covid-19. In addition, the clinical evolution of each patient was analyzed individually (Figures 13 to 17
10 and 20 to 21) and in groups (Figures 18 and 19), taking into account the following parameters: percentage of SpO₂, temperature, heart rate, respiratory rate, cough intervals, chest pain, headache, dyspnea, odynophagia, anosmia, loss of sense of taste, presence of arthralgia and myalgia, and
15 clinical improvement was documented in all cases.